AR057350A1 - Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas - Google Patents

Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas

Info

Publication number
AR057350A1
AR057350A1 ARP060102342A ARP060102342A AR057350A1 AR 057350 A1 AR057350 A1 AR 057350A1 AR P060102342 A ARP060102342 A AR P060102342A AR P060102342 A ARP060102342 A AR P060102342A AR 057350 A1 AR057350 A1 AR 057350A1
Authority
AR
Argentina
Prior art keywords
substituted
nr10r11
halogen
alkyl
unsubstituted
Prior art date
Application number
ARP060102342A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511452A external-priority patent/GB0511452D0/en
Priority claimed from GB0516787A external-priority patent/GB0516787D0/en
Priority claimed from GB0524968A external-priority patent/GB0524968D0/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR057350A1 publication Critical patent/AR057350A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/70—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/30—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

Composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto de la formula (1), en el que: R1 es -(CH2)n-R1a, en el que n es independientemente 0-6, y R1a se selecciona del grupo que consiste en: i) alquilo C1-6, que no está sustituido o está sustituido con 1-6 halogeno, hidroxi, ii) fenilo sustituido con R2a, R2b y R2c, iii) heterociclo sustituido con R2a, R2b y R2c, iv) cicloalquilo C3-6, que no está sustituido o está sustituido con alquilo C1-6, 1-6 halogeno, hidroxi o -NR10R11, v) -O-alquiloC1-6, que no está sustituido o está sustituido con 1-6 halogeno, hidroxi o -NR10R11, vi) -CO2R9, en el que R9 se selecciona independientemente de: a) hidrogeno, b) -alquiloC1-6, que no está sustituido o está sustituido con 1- 6 fluoro, c) bencilo, y d) fenilo, vii) -NR10R11, en el que R10 y R11 se seleccionan independientemente de: a) hidrogeno, b) -alquiloC1-6, que no está sustituido o está sustituido con hidroxi, 1-6 fluoro o -NR12R13, donde R12 y R13 se seleccionan independientemente de hidrogeno y -alquiloC1-6, c) -cicloalquiloC3-6, que no está sustituido o está sustituido con hidroxi, 1-6 fluoro o -NR12R13, d) bencilo, e) fenilo, y viii) -CONR10R11; R2 se selecciona del grupo consiste en: i) fenilo, que está sustituido con R2a, R2b y R2c, ii) heterociclo, que está sustituido con R2a, R2b y R2c, iii) alquilo C1-8, que no está sustituido o está sustituido con 1-6 halogeno, hidroxi, -NR10R11, fenilo o heterociclo, donde el fenilo o heterociclo está sustituido con R2a, R2b y R2c, iv) cicloalquilo C3-6, que no está sustituido o está sustituido con 1-6 halogeno, hidroxi o -NR10R11, y v) -alquilC1-6-cicloalquiloC3-6, que no está sustituido o está sustituido con 1-6 halogeno, hidroxi o -NR10R11; R2a, R2b y R2c se selecciona independientemente del grupo que consiste de: i) hidrogeno, ii) halogeno, iii) -alquiloC1-6, que no está sustituido o está sustituido con: a) 1-6 halogeno, b) fenilo, c) cicloalquiloC3-6, o d) -NR10R11, iv) -O-alquiloC1- 6, que no está sustituido o está sustituido con 1-6 halogeno, v) hidroxi, vi) -SCF3, vii) -SCHF2, viii) -SCH3, ix) -CO2R9 , x) -CN, xi) -SO2R9 , xii) -SO2-NR10R11, xiii) -NR10R11, xiv) -CONR10R11, y xv) -NO2, o dos de R2a, R2b y R2c están enlazados formando un grupo de formula (2), en el que r es 1 a 3; R3 se selecciona del grupo que consiste de: i) alquilo C1-6, que no está sustituido o está sustituido con 1-6 halogeno, hidroxilo, -NR10R11, o heterociclo, que está sustituido con R2a, R2b y R2c, ii) cicloalquilo C3-6, que no está sustituido o está sustituido con 1-6 halogeno, hidroxilo o -NR10R11, iii) -alquilC1-6-cicloalquiloC3-6, que no está sustituido o está sustituido con 1-6 halogeno, hidroxi o -NR10R11, y iv) -NR10R11, y v) heterociclo, que está sustituido con R2a, R2b y R2c; R4 y R5 se seleccionan independientemente del grupo que consiste de: i) hidrogeno, y ii) alquilo C1-6, que no está sustituido o está sustituido con halogeno o hidroxilo, o R4 y R5 tomados conjuntamente forman un anillo cicloalquilo C3-6; A se selecciona del grupo que consiste en: i) -O-, y ii) -NR10-; m es cero o uno, por lo que cuando m es cero R2 está unido directamente al carbonilo; y sus sales farmacéuticamente aceptables y sus enantiomeros y diastereoisomeros individuales.
ARP060102342A 2005-06-06 2006-06-05 Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas AR057350A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0511452A GB0511452D0 (en) 2005-06-06 2005-06-06 Therapeutic agents
GB0516787A GB0516787D0 (en) 2005-08-17 2005-08-17 Therapeutic agents
GB0524968A GB0524968D0 (en) 2005-12-08 2005-12-08 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR057350A1 true AR057350A1 (es) 2007-11-28

Family

ID=36636407

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102342A AR057350A1 (es) 2005-06-06 2006-06-05 Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas

Country Status (10)

Country Link
US (2) US7626056B2 (es)
EP (2) EP1891002B1 (es)
JP (1) JP5281395B2 (es)
AR (1) AR057350A1 (es)
AU (1) AU2006256583B2 (es)
CA (1) CA2609969C (es)
DO (1) DOP2006000125A (es)
PE (1) PE20061490A1 (es)
TW (1) TW200716531A (es)
WO (2) WO2006131713A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512251A (ja) * 2003-11-12 2007-05-17 メルク　エンド　カムパニー　インコーポレーテッド ４−フェニルピペリジンスルホニルグリシン輸送体インヒビター
EP1729772B8 (en) * 2004-03-24 2017-04-19 Merck Sharp & Dohme Corp. Heteroaryl piperidine glycine transporter inhibitors
EP1745018A1 (en) * 2004-04-29 2007-01-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
WO2005107469A2 (en) * 2004-05-05 2005-11-17 Merck & Co., Inc. Morpholinyl piperidine glycine transporter inhibitors
JP4646984B2 (ja) * 2004-09-30 2011-03-09 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピペリジングリシン輸送体阻害剤
WO2006067529A1 (en) * 2004-12-21 2006-06-29 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as glyt1 inhibitors
PE20061490A1 (es) 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
EP1899294B1 (en) * 2005-06-13 2015-03-18 Merck Sharp & Dohme Limited Therapeutic agents
GB0523998D0 (en) * 2005-11-25 2006-01-04 Merck Sharp & Dohme Therapeutic agents
AU2008341953B2 (en) * 2007-12-26 2013-05-02 Msd K.K. Sulfonyl substituted 6-membered ring derivative
AU2010295481A1 (en) * 2009-09-18 2012-03-08 Zalicus Pharmaceuticals Ltd. Aryl sulphone derivatives as calcium channel blockers
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
EP2595484B1 (en) * 2010-07-20 2017-10-18 Minerva Neurosciences, Inc. Use of cyclic amide derivatives to treat sleep disorders
EP3009421A1 (en) * 2013-06-10 2016-04-20 Taisho Pharmaceutical Co., Ltd. Glycine transporter inhibitor
US9708334B2 (en) 2014-04-24 2017-07-18 Dart Neuroscience (Cayman) Ltd. Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors
TWI601712B (zh) 2014-11-05 2017-10-11 達特神經科學（開曼）有限責任公司 作為ｇｌｙｔ１抑制劑之經取代之氮雜環丁基化合物
ES2910528T3 (es) 2014-12-02 2022-05-12 Minerva Neurosciences Inc Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
CN106467477A (zh) * 2016-08-26 2017-03-01 天津雅奥科技发展有限公司 一种合成化合物（1‑环丙基‑1‑氰基‑4‑环己酮）的新方法
CN106916089B (zh) * 2017-03-14 2018-10-19 大连九信精细化工有限公司 一种选择性合成顺式4-正戊基环己硫醇的制备方法
CN111511353A (zh) 2017-06-21 2020-08-07 田边三菱制药株式会社 耐胃液的控释口服剂型
CA3108882A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
CN115038690A (zh) 2020-01-31 2022-09-09 索尔维公司 用于制造卤代烷基取代的吡啶化合物的方法
CN114426494B (zh) * 2022-01-13 2023-09-15 江苏海洋大学 一种具有作用于taar激动剂的取代甲胺类衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127191A (en) * 1996-12-03 2000-10-03 3-Dimensional Pharmaceuticals, Inc. Aminobenzenedicarboxylic acid-based combinatorial libraries
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
KR20040066896A (ko) * 2001-12-12 2004-07-27 에프. 호프만-라 로슈 아게 치환된 사이클로헥산 유도체
GB0223039D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
JP2007512251A (ja) * 2003-11-12 2007-05-17 メルク　エンド　カムパニー　インコーポレーテッド ４−フェニルピペリジンスルホニルグリシン輸送体インヒビター
EP1729772B8 (en) * 2004-03-24 2017-04-19 Merck Sharp & Dohme Corp. Heteroaryl piperidine glycine transporter inhibitors
EP1745018A1 (en) * 2004-04-29 2007-01-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
WO2005107469A2 (en) * 2004-05-05 2005-11-17 Merck & Co., Inc. Morpholinyl piperidine glycine transporter inhibitors
JP4646984B2 (ja) * 2004-09-30 2011-03-09 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピペリジングリシン輸送体阻害剤
WO2006067529A1 (en) * 2004-12-21 2006-06-29 Merck Sharp & Dohme Limited Piperidine and azetidine derivatives as glyt1 inhibitors
PE20061490A1 (es) 2005-06-06 2007-02-09 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1

Also Published As

Publication number Publication date
US7851638B2 (en) 2010-12-14
JP2008542348A (ja) 2008-11-27
EP1891002A1 (en) 2008-02-27
AU2006256583A1 (en) 2006-12-14
EP1893566B1 (en) 2013-02-13
US20060276655A1 (en) 2006-12-07
US20100029726A1 (en) 2010-02-04
US7626056B2 (en) 2009-12-01
TW200716531A (en) 2007-05-01
EP1891002B1 (en) 2012-05-30
WO2006131711A1 (en) 2006-12-14
CA2609969C (en) 2015-10-27
EP1893566A1 (en) 2008-03-05
WO2006131713A1 (en) 2006-12-14
CA2609969A1 (en) 2006-12-14
AU2006256583B2 (en) 2012-01-12
PE20061490A1 (es) 2007-02-09
DOP2006000125A (es) 2006-12-31
JP5281395B2 (ja) 2013-09-04

Similar Documents

Publication Publication Date Title
AR057350A1 (es) Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas
CO6160296A2 (es) Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PE20130155A1 (es) Derivados de ariletinilo
CO6400139A2 (es) Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
ECSP099395A (es) Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico
AR059184A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
AR050266A1 (es) Derivados de bencil-triazolona como inhibidores no nucleosidos de transcriptasa inversa
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
AR073136A1 (es) Compuestos de pirrol
ES2630079T3 (es) Moduladores de la ruta del complemento y usos de los mismos
ES2613538T3 (es) Derivados de arilamida como bloqueadores de TTX-S
CO6290763A2 (es) Derivados de benzamidas, carboxamidas y nicotinamidas como moduladores alostericos positivos y sus composiciones
AR065854A1 (es) Derivados de 1-oxa-3,9-diaza-espiro[5.5]undecan-2-ona,medicamentos que los contienen y usos como agentes anti vih,entre otros.
NI200900032A (es) Compuestos de pirido (2, 3-d) pirimidinonay su uso como inhibidores de pi3
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
CO5540343A2 (es) Derivados de furano y tiofeno que activan receptores activados por el proliferador de la peroxisoma humana
PA8663901A1 (es) Derivados del (1,5-difenil-1h-pirazol-3-il)oxadiazol, su prepararacion y su aplicacion en terapéutica
CO6300861A2 (es) Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos
CO6460743A2 (es) Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica
CO6140030A2 (es) Derivados de 4-bencilftalazinona 2-sustituidos como antagonistas de histamina h1 y h3
NI201000049A (es) Método para producir 2'-desoxi-5-azacitidina (decitabina)
AR045859A1 (es) Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure